Intensity Therapeutics, Inc. (INTS): Total Assets
$14.10M
As of 2025-12-31
$11.52M
As of 2026-06-30
+100.2%
3-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $14.10M | +194.8% | 2026-03-27, Balance as of period end |
| 2024-12-31 | $4.78M | -72.3% | 2026-03-27, Balance as of period end |
| 2023-12-31 | $17.30M | +884.3% | 2025-03-13, Balance as of period end |
| 2022-12-31 | $1.76M | n/a | 2024-03-14, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Intensity Therapeutics, Inc. (INTS) | 2025-12-31 | $14.10M | +194.8% |
| MiNK Therapeutics, Inc. (INKT) | 2025-12-31 | $14.24M | +148.9% |
| BioAtla, Inc. (BCAB) | 2025-12-31 | $13.83M | -73.6% |
| Entera Bio Ltd. (ENTX) | 2025-12-31 | $15.99M | +70.3% |
| Scinai Immunotherapeutics Ltd. (SCNI) | 2025-12-31 | $11.63M | -13.5% |
| Outlook Therapeutics, Inc. (OTLK) | 2025-09-30 | $18.58M | -35.5% |
| Curis Inc (CRIS) | 2025-12-31 | $19.97M | -51.6% |
| Dyadic International Inc (DYAI) | 2025-12-31 | $9.95M | +0.2% |
| Atara Biotherapeutics, Inc. (ATRA) | 2025-12-31 | $20.23M | -81.5% |
Compare INTS, INKT, BCAB, ENTX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗